FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|July 29, 2010
Regulatory Roundup: European Medicines Agency Issues Drug Review Update; And More.
Author(s)Pharmaceutical Technology Editors
European Medicines Agency Issues Drug Review Update; And More
Advertisement
The European Medicines Agency's Committee for Medical Products for Human Use issued an
The US Food and Drug Administration issued a
Advertisement
Related to this article
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Boyang Wang, Immortal Dragons, discusses how the FDA’s Expedited IND Pilot must prove efficiency as sponsors chase the fastest route to valid first-in-human data.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5